Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Group 1: Transaction Overview - Spartan Capital Securities, LLC closed a $5.0 million private placement for Lixte Biotechnology Holdings, Inc. on July 2, 2025, serving as the exclusive placement agent [1][2]. - The offering included the sale of Common Stock (or Pre-Funded Warrants), Series B Convertible Preferred Stock, and Common Warrants to accredited investors [2]. - The company received gross proceeds of approximately $5.0 million, with $4.0 million received at closing and the remaining $1.0 million to be received upon effectiveness of a resale registration statement [3]. Group 2: Use of Proceeds - Proceeds from the offering will be used for general corporate purposes and working capital [3]. Group 3: Company Background - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing cancer therapies based on novel biological pathways [8]. - The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has shown promise in enhancing the effectiveness of chemotherapy and immunotherapy, with clinical trials underway for colon, small cell lung, and sarcoma cancers [8]. Group 4: Representation and Support - Lixte was represented by TroyGould PC, while Spartan Capital Securities was represented by Kaufman & Canoles, P.C. [4].